How transcription factor mutations shape diabetes risk
Diabetes affects hundreds of millions of people worldwide. The disease features elevated blood glucose levels and disrupted fat and protein metabolism. The musculoaponeurotic fibrosarcoma, or MAF, family of transcription factors regulate various processes in tissue development, including hormone production in pancreatic islet cells. Within this family, MAFA and MAFB are essential for development and maturation of insulin- and glucagon-producing cells.

Previous research showed that MAFA and MAFB expression is affected in diabetes, both Type 1 and Type 2. In addition, a mutation in MAFA that prevents phosphorylation of a key serine residue causes monogenic diabetes. Mutation of the equivalent residue in MAFB leads to a pediatric multisystem disorder. In a recent Journal of Biological Chemistry , Jeeyeon Cha, Xin Tong and Katie Coate from Vanderbilt University and collaborators in the U.S. examined how mutations in conserved DNA-binding domains of the MAF proteins impact their regulation of the insulin gene. The authors used targeted mutagenesis and artificial intelligence structure prediction using AlphaFold 2 for their analysis.
They found one MAFA variant, with a mutation in the conserved DNA-binding region, that exhibited normal activity. The equivalent mutation in MAFB did not retain normal activity. Therefore, the researchers searched for structural differences between the MAFA and MAFB proteins outside of the DNA-binding region that might also contribute to its activity. Their AlphaFold 2 models showed that the two proteins differed in the C-terminal domains. The researchers created chimeras by exchanging the two C-terminal domains of MAFA and MAFB, which changed how each protein regulated the insulin gene. These results help clarify differences between MAFA and MAFB, which of their domains affect activity and possible ways that they contribute to different disease states.
Future studies will focus on regions of MAFA and MAFB that may interact with other coregulators of the insulin gene.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ« paper.